LXRX
LEXICON PHARMACEUTICALS, INC.
$1.88
-1.57%
$835.1M
No data for this timeframe.
Vol
Market Cap$835.1M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (73%)
Inst. Holders8 funds
Inst. Value$57.1M
Inst. Activity1 buys / 1 sells
Insider Activity4B / 0S
Insider Net $$369.7K
Reddit Sentiment50° Neutral
SEC Reports5
Press Releases3
Recent Activity
Jun 3, 2026
other
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmaco
Jun 3, 2026
Insider
DEBBANE RAYMOND sold 89,312 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
DEBBANE RAYMOND sold 89,312 shares
Director @ $0.00 ($0.00)
Jun 3, 2026
Insider
BARKER SAM L sold 89,312 shares
Director @ $0.00 ($0.00)
May 6, 2026
SEC
Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 million funded at clos
8-K — Impact 4/10
Apr 30, 2026
SEC
Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B Convertible Preferre
8-K — Impact 6/10
Apr 30, 2026
SEC
Lexicon Pharmaceuticals announced it will release Q1 2026 financial results on May 7, 2026. The filing does not contain
PRESS-RELEASE — Impact 2/10
Inst.
BANK OF AMERICA CORP — ADD
102,097 shares ($117.4K)
Price Targets
$3.72
+97.9% upside
Strong Buy
Current $1.88
Low $1.50
Median $3.10
High $6.00
5 analysts
$1.50
$6.00
Analyst Ratings
3Strong Buy
5Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 11, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy → Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.05 ▲ +8.7% | $-0.06 — $-0.03 | -602% YoY | 5 |
| Next Q | $-0.06 ▼ -19.1% | $-0.07 — $-0.05 | -49% YoY | 5 |
| Current FY | $-0.16 ▲ +12.4% | $-0.18 — $-0.14 | -13% YoY | 5 |
| Next FY | $-0.21 ▲ +0.9% | $-0.27 — $-0.11 | -30% YoY | 5 |
Latest Reports
NEUTRAL
8-K
4/10
Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 million funded at clos
May 6, 2026
BEARISH
8-K
6/10
Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B Convertible Preferre
Apr 30, 2026
MIXED
Press
6/10
Lexicon Pharmaceuticals presented new clinical data for sotagliflozin at the American College of Cardiology Annual Meeti
Mar 24, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $43.5M | TRIM |
| VANGUARD GROUP INC | $11.0M | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $1.2M | ADD |
| TWO SIGMA INVESTMENTS, LP | $732.9K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $302.7K | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | DEBBANE RAYMOND | M | $0.00 |
| Jun 3, 2026 | DEBBANE RAYMOND | M | $0.00 |
| Jun 3, 2026 | BARKER SAM | M | $0.00 |
| Jun 3, 2026 | BARKER SAM | M | $0.00 |
| Jun 3, 2026 | Amouyal Philippe | M | $0.00 |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
8 institutional holders with $57.1M total value (49,691,574 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, CHARLES.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 37,834,207 | $43.5M | 76.1% | TRIM -33.5% |
| 2 | VANGUARD GROUP INC | 9,606,549 | $11.0M | 19.3% | — |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,055,123 | $1.2M | 2.1% | ADD +29.6% |
| 4 | TWO SIGMA INVESTMENTS, LP | 637,308 | $732.9K | 1.3% | ADD +38.4% |
| 5 | RENAISSANCE TECHNOLOGIES LLC | 263,254 | $302.7K | 0.5% | NEW |
| 6 | MORGAN STANLEY | 193,035 | $222.0K | 0.4% | ADD +28.6% |
| 7 | BANK OF AMERICA CORP /DE/ | 102,097 | $117.4K | 0.2% | ADD +76.6% |
| 8 | WELLS FARGO & COMPANY/MN | 1 | $1.00 | 0.0% | NEAR_EXIT -99.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | ADD | 57,804 | 102,097 | +76.6% | $117.4K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 301 | 1 | -99.7% | $1.00 | 2025-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 883,227 | 1,144,632 | +29.6% | $1.5M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 403,922 | 559,008 | +38.4% | $754.7K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 292,400 | — | $394.7K | 2025-Q3 |
| MORGAN STANLEY | ADD | 131,393 | 169,018 | +28.6% | $228.2K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 32,097 | 57,804 | +80.1% | $78.0K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 26,423 | 301 | -98.9% | $406.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 403,922 | — | $382.0K | 2025-Q2 |
| UBS Group AG | NEAR_EXIT | 2,095,340 | 400,732 | -80.9% | $379.1K | 2025-Q2 |
| MORGAN STANLEY | NEAR_EXIT | 641,629 | 131,393 | -79.5% | $124.3K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | TRIM | 96,387 | 32,097 | -66.7% | $30.3K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 63,928 | 26,423 | -58.7% | $25.0K | 2025-Q2 |
| FMR LLC | TRIM | 51,970,455 | 34,543,197 | -33.5% | $15.9M | 2025-Q1 |
| UBS Group AG | DOUBLED | 686,117 | 2,095,340 | +205.4% | $966.0K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 51,141 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 139,992 | 686,117 | +390.1% | $507.0K | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 51,141 | — | $37.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,417,295 | — | $2.2M | 2024-Q3 |
| MORGAN STANLEY | ADD | 354,036 | 454,977 | +28.5% | $714.3K | 2024-Q3 |
16 unique insiders with 4 transactions. Net insider value: $369.7K ($369.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | DEBBANE RAYMOND | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | DEBBANE RAYMOND | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | BARKER SAM L | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | BARKER SAM L | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Amouyal Philippe | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Amouyal Philippe | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Cheung Ivan | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Cheung Ivan | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Sullivan Diane E. | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Sullivan Diane E. | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | SOBECKI CHRISTOPHER J | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Swain Judith L | Director | M | 89,312 | $0.00 | $0.00 |
| Jun 3, 2026 | Swain Judith L | Director | M | 89,312 | $0.00 | $0.00 |
| May 1, 2026 | DEBBANE RAYMOND | Director | A | 35,714 | $0.00 | $0.00 |
| May 1, 2026 | DEBBANE RAYMOND | Director | A | 43,478 | $0.00 | $0.00 |
| May 1, 2026 | Swain Judith L | Director | A | 35,714 | $0.00 | $0.00 |
| May 1, 2026 | Swain Judith L | Director | A | 43,478 | $0.00 | $0.00 |
| May 1, 2026 | Cheung Ivan | Director | A | 35,714 | $0.00 | $0.00 |
| May 1, 2026 | Cheung Ivan | Director | A | 43,478 | $0.00 | $0.00 |
| May 1, 2026 | BARKER SAM L | Director | A | 35,714 | $0.00 | $0.00 |
| May 1, 2026 | BARKER SAM L | Director | A | 43,478 | $0.00 | $0.00 |
| May 1, 2026 | SOBECKI CHRISTOPHER J | Director | A | 35,714 | $0.00 | $0.00 |
| May 1, 2026 | SOBECKI CHRISTOPHER J | Director | A | 43,478 | $0.00 | $0.00 |
| May 1, 2026 | Amouyal Philippe | Director | A | 35,714 | $0.00 | $0.00 |
| May 1, 2026 | Amouyal Philippe | Director | A | 43,478 | $0.00 | $0.00 |
| Apr 30, 2026 | Artal Participations S.a r.l. | Director | M | 408,434.7 | $0.00 | $0.00 |
| Apr 30, 2026 | Artal Participations S.a r.l. | Director | A | 408,434.7 | $0.00 | $0.00 |
| Apr 30, 2026 | Artal Participations S.a r.l. | Director | M | 20,421,735 | $0.00 | $0.00 |
| Feb 28, 2026 | Martens Rachel Yap | SVP, Partnerships & Corp Strat | M | 67,090 | $0.00 | $0.00 |
| Feb 28, 2026 | Gopinathan Suma | SVP, Discovery | M | 14,000 | $0.00 | $0.00 |
| Feb 28, 2026 | Crum Brian T | SVP, General Counsel & Secr. | M | 33,457 | $0.00 | $0.00 |
| Feb 28, 2026 | Exton Michael | Chief Executive Officer | M | 503,263 | $0.00 | $0.00 |
| Feb 28, 2026 | McDermott Wendy | SVP, Human Resources | M | 27,697 | $0.00 | $0.00 |
| Feb 28, 2026 | DeFrancesco Lisa | SVP, IR and Corp Comm | M | 24,674 | $0.00 | $0.00 |
| Feb 28, 2026 | Coiante Scott M | SVP, Chief Financial Officer | M | 160,237 | $0.00 | $0.00 |
| Feb 28, 2026 | DeFrancesco Lisa | SVP, IR and Corp Comm | M | 24,674 | $0.00 | $0.00 |
| Feb 28, 2026 | Granowitz Craig B | SVP, Chief Medical Officer | M | 35,790 | $0.00 | $0.00 |
| Feb 28, 2026 | Gopinathan Suma | SVP, Discovery | M | 14,000 | $0.00 | $0.00 |
| Feb 28, 2026 | McDermott Wendy | SVP, Human Resources | M | 27,697 | $0.00 | $0.00 |
| Feb 28, 2026 | Martens Rachel Yap | SVP, Partnerships & Corp Strat | M | 67,090 | $0.00 | $0.00 |
| Feb 28, 2026 | Granowitz Craig B | SVP, Chief Medical Officer | M | 35,790 | $0.00 | $0.00 |
| Feb 28, 2026 | Crum Brian T | SVP, General Counsel & Secr. | M | 69,386 | $0.00 | $0.00 |
| Feb 28, 2026 | Coiante Scott M | SVP, Chief Financial Officer | M | 160,237 | $0.00 | $0.00 |
| Feb 28, 2026 | Exton Michael | Chief Executive Officer | M | 503,263 | $0.00 | $0.00 |
| Feb 25, 2026 | DEBBANE RAYMOND | Director | BUY | 2,000 | $1.49 | $3.0K |
| Feb 23, 2026 | DEBBANE RAYMOND | Director | BUY | 100,000 | $1.47 | $147.0K |
| Feb 20, 2026 | DEBBANE RAYMOND | Director | BUY | 100,000 | $1.48 | $147.8K |
| Feb 19, 2026 | DEBBANE RAYMOND | Director | BUY | 50,000 | $1.44 | $72.0K |
| Feb 12, 2026 | DeFrancesco Lisa | SVP, IR and Corp Comm | A | 257,530 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 4.4/10.
NEUTRAL
8-K
4/10
Lexicon Pharmaceuticals entered into a $100 million loan facility with Hercules Capital, with $55 mi
May 6, 2026
BEARISH
8-K
6/10
Lexicon Pharmaceuticals filed an 8-K reporting the automatic conversion of all outstanding Series B
Apr 30, 2026
NEUTRAL
PRESS-RELEASE
2/10
Lexicon Pharmaceuticals announced it will release Q1 2026 financial results on May 7, 2026. The fili
Apr 30, 2026
NEUTRAL
DEFA14A
3/10
Lexicon Pharmaceuticals, Inc. has filed a definitive additional materials proxy statement (DEFA14A)
Mar 16, 2026
BULLISH
8-K
7/10
Lexicon Pharmaceuticals reported Q4 2025 financial results with $5.5 million in revenue, driven by l
Mar 5, 2026
MIXED
6/10
Lexicon Pharmaceuticals presented new clinical data for sotagliflozin at the American College of Car
Mar 24, 2026
BULLISH
7/10
Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX985
Mar 23, 2026
MIXED
6/10
Lexicon Pharmaceuticals reported Q4 and full-year 2025 financial results with significantly reduced
Mar 5, 2026
Current analyst consensus: Buy (73% buy). Based on 11 analysts: 3 strong buy, 5 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$3.72 mean target
+97.9% upside
Strong Buy (2.00)
$1.50 Low
$6.00 High
| Metric | Value |
|---|---|
| Current Price | $1.88 |
| Target Low | $1.50 |
| Target Mean | $3.72 |
| Target Median | $3.10 |
| Target High | $6.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.05 | $-0.06 | $-0.03 | -602.3% | +8.7% | — | $0.0B | -86.2% | 5 |
| Next Q 2026-09-30 |
$-0.06 | $-0.07 | $-0.05 | -48.9% | -19.1% | — | $0.0B | -78.3% | 5 |
| Current FY 2026-12-31 |
$-0.16 | $-0.18 | $-0.14 | -13.3% | +12.4% | 2↑ 0↓ | $0.0B | -23.4% | 5 |
| Next FY 2027-12-31 |
$-0.21 | $-0.27 | $-0.11 | -30.0% | +0.9% | 0↑ 1↓ | $0.0B | -47.2% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.050 | |
| 7d ago | $-0.050 | |
| 30d ago | $-0.055 | +0.005 |
| 60d ago | $-0.055 | +0.005 |
| 90d ago | $-0.055 | +0.005 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 10, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 5, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Apr 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Mar 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Feb 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% | |
| Jan 1, 2026 | 3 | 5 | 3 | 0 | 0 | 73% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
3 mentions
0 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Apr 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Feb 19, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
LXRX set to spike
▲ 1
💬 0
⚡ 0.0
Jun 3, 2026
other
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function grou
May 28, 2026
other
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
<p align="left">THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Jg-AJURJmAVl73VhxWU7Kgpw_
May 7, 2026
earnings
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
<p align="center"><strong><em>SONATA-HCM anticipated to be fully enrolled mid-2026 </em></strong></p>
May 7, 2026
earnings_calendar
LXRX Q1 2026 Earnings Scheduled — 2026-05-07
May 1, 2026
short_volume
Short Volume: LXRX — 59.3% short (0.4M / 0.7M)
Short: 387,102 | Exempt: 0 | TRF Vol: 652,750 | Short Ratio: 59.3% | Off-exchange volume (dark pool + OTC)
Apr 30, 2026
earnings
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
<p align="left">THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company wi
Apr 30, 2026
earnings_calendar
LXRX Q1 2026 Earnings Scheduled — 2026-04-30
Apr 22, 2026
Enforcement
HSR Early Termination: Stichting Administratiekantoor Westend; Lexicon Pharmaceuticals, Inc.
The FTC granted early termination of the HSR Act waiting period for a transaction involving Stichting Administratiekantoor Westend; Lexicon Pharmaceut
Apr 17, 2026
routine
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
<p align="center"><em> Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optima
Apr 6, 2026
short_volume
Short Volume: LXRX — 63.0% short (0.5M / 0.8M)
Short: 481,359 | Exempt: 1 | TRF Vol: 764,472 | Short Ratio: 63.0% | Off-exchange volume (dark pool + OTC)
Apr 2, 2026
short_volume
Short Volume: LXRX — 71.1% short (0.9M / 1.2M)
Short: 851,241 | Exempt: 30 | TRF Vol: 1,196,609 | Short Ratio: 71.1% | Off-exchange volume (dark pool + OTC)
Mar 24, 2026
fda
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sot
Mar 23, 2026
fda
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
<p align="center"><em>LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associa
Mar 5, 2026
earnings
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates
<p align="center"><strong><em>Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM
Mar 5, 2026
earnings_calendar
LXRX Q4 2025 Earnings After Market Close — 2026-03-05
Mar 3, 2026
other
Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences
<p align="left">THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company m